Comments
BDR Pharmaceuticals on Monday said it has launched the generic version of Nintedanib drug for treatment of Idiopathic Pulmonary Fibrosis (IPF).
The generic version of the drug has been launched under the brand name ‘Nintenib’ in the country.
IPF is a lung disorder where there is scarring of the lungs due to an unknown cause, BDR Pharmaceuticals said in a statement.
“We are proud to launch the generic version of the drug for lung fibrosis in India especially during a time when there is an ardent need of the medicine for Covid-19 patients,” BDR Pharmaceuticals CMD Dharmesh Shah said.
The company’s drug is priced at Rs 750 (100 mg) and Rs 900 (150 mg) for a pack of 10 tablets, the company said.
Currently, there are two clinical trials being conducted to study the safety and efficacy of Nintedanib for the treatment of moderately to critically ill Covid-19 patients suffering from IPF, it added.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.